BioCentury

8:00 AM GMT, Feb 17, 2003
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Politics, Policy & Law

A shot in the arm for Australian biotech

Cephalon Inc.'s acquisition of SIRTeX Medical Technologies Ltd. for $161 million in cash provides proof-of-concept that Australian biotech can create value that attracts the attention of the outside world. But given their geographic and temporal distance from the rest of the world, Australian companies need to build additional infrastructure to connect science with business on a global level. And, as in the rest of the

Read the full 653 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.